Nothing Special   »   [go: up one dir, main page]

SA523441069B1 - EphA4 جسم مضاد لـ - Google Patents

EphA4 جسم مضاد لـ

Info

Publication number
SA523441069B1
SA523441069B1 SA523441069A SA523441069A SA523441069B1 SA 523441069 B1 SA523441069 B1 SA 523441069B1 SA 523441069 A SA523441069 A SA 523441069A SA 523441069 A SA523441069 A SA 523441069A SA 523441069 B1 SA523441069 B1 SA 523441069B1
Authority
SA
Saudi Arabia
Prior art keywords
seq
heavy chain
light chain
epha4
cdr2
Prior art date
Application number
SA523441069A
Other languages
English (en)
Inventor
إيجي أنوي،
تومومي كاواكاتسو،
أكي ناكاتاني،
أكيو يامادا،
Original Assignee
إيساي آر آند دي منجمنت كو.، ليمتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by إيساي آر آند دي منجمنت كو.، ليمتد filed Critical إيساي آر آند دي منجمنت كو.، ليمتد
Publication of SA523441069B1 publication Critical patent/SA523441069B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

يتعلق الاختراع الحالي بجسم مضاد لـEphA4 قادر على الارتباط بـEphA4 وتعزيز انشطاره، وتركيبة صيدلانية تشتمل على الجسم المضاد بوصفه مكوناً نشطاً. يشتمل الجسم المضاد لـEphA4 على سلسلة ثقيلة تشتمل على CDR1 ثقيلة السلسلة بالمتوالية رقم: 30؛ وCDR2 ثقيلة السلسلة بالمتوالية رقم: 31؛ و CDR3ثقيلة السلسلة بالمتوالية رقم: 32؛ وسلسلة خفيفة تشتمل على CDR1خفيفة السلسلة بالمتوالية رقم: 33؛ و CDR2خفيفة السلسلة بالمتوالية رقم: 34؛ و CDR3خفيفة السلسلة بالمتوالية رقم: 35؛ أو سلسلة ثقيلة تشتمل على CDR1 ثقيلة السلسلة بالمتوالية رقم: 42؛ وCDR2 ثقيلة السلسلة بالمتوالية رقم: 31؛ و CDR3ثقيلة السلسلة بالمتوالية رقم: 43؛ وسلسلة خفيفة تشتمل على CDR1خفيفة السلسلة بالمتوالية رقم: 44؛ و CDR2خفيفة السلسلة بالمتوالية رقم: 34؛ و CDR3 خفيفة السلسلة بالمتوالية رقم: 35. شكل 1
SA523441069A 2020-12-24 2023-06-06 EphA4 جسم مضاد لـ SA523441069B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020214958 2020-12-24
PCT/JP2021/047534 WO2022138708A1 (ja) 2020-12-24 2021-12-22 抗ＥｐｈＡ４抗体

Publications (1)

Publication Number Publication Date
SA523441069B1 true SA523441069B1 (ar) 2024-07-02

Family

ID=82157006

Family Applications (1)

Application Number Title Priority Date Filing Date
SA523441069A SA523441069B1 (ar) 2020-12-24 2023-06-06 EphA4 جسم مضاد لـ

Country Status (16)

Country Link
US (1) US20230357386A1 (ar)
EP (1) EP4269588A1 (ar)
JP (1) JPWO2022138708A1 (ar)
KR (1) KR20230123923A (ar)
CN (1) CN116528899A (ar)
AR (1) AR124467A1 (ar)
AU (1) AU2021410893A1 (ar)
CA (1) CA3192342A1 (ar)
CL (1) CL2023001651A1 (ar)
CO (1) CO2023005482A2 (ar)
IL (1) IL303223A (ar)
MX (1) MX2023004850A (ar)
PE (1) PE20241066A1 (ar)
SA (1) SA523441069B1 (ar)
TW (1) TW202241949A (ar)
WO (1) WO2022138708A1 (ar)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
WO2012081502A1 (ja) * 2010-12-17 2012-06-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法
GB201107996D0 (en) 2011-05-13 2011-06-29 Vib Vzw EphA4 is a diease modifier in motor neuron disease
US10934360B2 (en) 2014-07-31 2021-03-02 The Hong Kong University Of Science And Technology Human monoclonal antibodies against EPHA4 and their use
MX2018002164A (es) * 2015-09-08 2018-09-12 Eisai R&D Man Co Ltd Anticerpo anti-epha4.

Also Published As

Publication number Publication date
JPWO2022138708A1 (ar) 2022-06-30
CN116528899A (zh) 2023-08-01
AR124467A1 (es) 2023-03-29
EP4269588A1 (en) 2023-11-01
AU2021410893A9 (en) 2024-07-25
CO2023005482A2 (es) 2023-05-19
WO2022138708A1 (ja) 2022-06-30
MX2023004850A (es) 2023-05-10
CA3192342A1 (en) 2022-06-30
IL303223A (en) 2023-07-01
CL2023001651A1 (es) 2023-12-15
US20230357386A1 (en) 2023-11-09
PE20241066A1 (es) 2024-05-13
TW202241949A (zh) 2022-11-01
AU2021410893A1 (en) 2023-06-08
KR20230123923A (ko) 2023-08-24

Similar Documents

Publication Publication Date Title
MY187741A (en) Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph
RS53924B1 (en) NOTCH-BINDING AGENTS AND ANTAGONISTS AND PROCEDURES FOR THEIR USE
MX2019001897A (es) Anticuerpo anti-lag-3.
PE20120306A1 (es) Anticuerpos anti-egfr y vectores que los codifican
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
CO6231009A2 (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
PE20120429A1 (es) Proteinas de enlace de miostatina
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
NZ605980A (en) Anti-fap antibodies and methods of use
CO5631451A2 (es) Anticuerpo especifico para cd22 humano y composicion farmaceutica derivada
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
NZ717847A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
RS54393B1 (en) HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
PE20130159A1 (es) Anticuerpos anti-cd40
NZ607711A (en) Antibodies directed to her-3 and uses thereof
NZ625807A (en) Human anti-b7rp1 neutralizing antibodies
PE20091205A1 (es) Anticuerpo anti-receptor de il-6
PE20131334A1 (es) Anticuerpo igg1 humanizado
PE20141151A1 (es) Proteinas de union al antigeno cd27l
NZ596712A (en) Anti cxcr4 antibodies for the treatment of hiv
PE20211293A1 (es) Anticuerpos monoclonales antagonistas contra cd40 y sus usos
PE20121494A1 (es) Anticuerpos anti notch-1